Japan · Delayed Price · Currency is JPY Oncolys BioPharma Company Description
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia.
Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer.
The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and aicardi-goutieres syndrome; OBP-702, which is in preclinical trial to treat pancreatic cancer; OBP-201, which is in preclinical trial to treat viral infections; OBP-702 for the treatment of ophthalmology which is in preclinical trial.
In addition, it develops TelomeScan (OBP-401 and OBP-1101), which is in pilot study trial to treat cancer testing.
The company was incorporated in 2004 and is headquartered in Minato, Japan.
| Country | Japan |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Yasuo Urata |
Contact Details
Address: 4-1-28 Toranomon Minato, 105-0001 Japan | |
| Phone | 81 3 5472 1578 |
| Website | oncolys.com |
Stock Details
| Ticker Symbol | 4588 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3202170001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yasuo Urata | Chief Executive Officer |